Paics Inhibition Is a Potential Therapeutic Strategy for MYC-Positive DLBCL
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-129613
Abstract: Diffuse large B-cell lymphoma (DLBCL) is among the most common hematological malignancies with varying prognosis. As many as forty percent of patients eventually experience relapsed/refractory disease after combinatorial chemo-immunotherapies, R-CHOP, and prognosis after relapse is… read more here.
Keywords: dlbcl; positive dlbcl; myc positive; myc ... See more keywords
Efficacy and prognosis of pola-R-CHP in CD5-positive DLBCL: Rapid response, long-term survival benefits, and early therapeutic optimization
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-1916
Abstract: Background and Aim: CD5-positive diffuse large B-cell lymphoma (DLBCL) represents an aggressive subtype with particularly poor clinical outcomes. Following China's approval of Pola-R-CHP (polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone) for first-line DLBCL… read more here.
Keywords: pola chp; treatment; dlbcl; positive dlbcl ... See more keywords
Clinicopathological and prognostic features of hepatitis B virus-associated diffuse large B-cell lymphoma: a single-center retrospective study in China
Sign Up to like & getrecommendations! Published in 2021 at "Infectious Agents and Cancer"
DOI: 10.1186/s13027-021-00396-x
Abstract: Background While the epidemiologic association between hepatitis B virus (HBV) infection and diffuse large B-cell lymphoma (DLBCL) is established, little is known about the pathological characteristics and outcome of DLBCL arising in patients with HBV… read more here.
Keywords: positive dlbcl; dlbcl; large cell; hepatitis virus ... See more keywords